off-label use of glp-1 agonists for obesity in 2016 Prescribing patterns glucagon-like peptide-1 receptor the Swedish capital region—a register-based cross-sectional study | European Journal of Clinical Pharmacology US adult obesity rate drops
Description
Acute pancreatitis has been reported in connection with GLP-1 RAs use [121, 124,125,126], though the data are insufficient to establish a causal relationship
A brief mechanistic summary of potential pathways targeted by GLP-1s in relation to CVD is provided in Fig
These side effects tend to be most prominent at the initiation of therapy and improve with continued use in many patients
GLP-1 medications should be stopped if pancreatitis develops, and should likely be avoided in anyone with pre-existing gastroparesis
Zobel EH, Ripa RS, von Scholten BJ, Rotbain Curovic V, Kjaer A, Hansen TW, et al
